Loading…

Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy

We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DC...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2021-09, Vol.60 (9), p.1154-1160
Main Authors: Onal, Cem, Yuce Sari, Sezin, Yavas, Guler, Oymak, Ezgi, Birgi, Sumerya Duru, Yigit, Ecem, Guler, Ozan Cem, Gultekin, Melis, Akyurek, Serap, Yildiz, Ferah
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163
cites cdi_FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163
container_end_page 1160
container_issue 9
container_start_page 1154
container_title Acta oncologica
container_volume 60
creator Onal, Cem
Yuce Sari, Sezin
Yavas, Guler
Oymak, Ezgi
Birgi, Sumerya Duru
Yigit, Ecem
Guler, Ozan Cem
Gultekin, Melis
Akyurek, Serap
Yildiz, Ferah
description We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DCRT (265 patients, 41%) or with IMRT (381 patients, 59%) between April 2007 and August 2019 were retrospectively analyzed. The primary endpoints were treatment-related acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. The secondary endpoints were LC and overall survival (OS) and disease-free survival (DFS). Median follow-up time was 37 months. The rates for acute GI and GU toxicities of any grade for the entire group were 55.6% and 46.8%, respectively. Acute grade ≥2 GI toxicity was significantly less in patients treated with IMRT compared to those treated with 3DCRT (11.0% vs. 19.2%, p=.004). However, no significant difference grade ≥2 GU toxicities was observed between the 3DCRT and IMRT groups (15.1% vs. 11.0%; p=.15). Acute grade ≥2 GI and GU toxicities were higher in patients receiving systemic chemotherapy, while paraaortic field irradiation increases only the risk of acute grade ≥2 GI toxicity. Estimated 3-year late grade ≥3 GI toxicity rates in the 3DCRT- and IMRT-treated patients were 4.6% and 1.9% (p= .03), respectively. The patients treated with adjuvant ChT had higher rates of late serious GI complications than those without adjuvant ChT. No significant difference in terms of survival and disease control was observed between the 3DCRT and IMRT treatment groups. No significant factor for LC was found in the multivariate analysis. In this multicentric study involving one of largest patient population, we found that IMRT-treated EC patients showed comparable clinical outcomes but with a lower incidence of GI toxicities compared with those treated with 3DCRT.
doi_str_mv 10.1080/0284186X.2021.1926537
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_0284186X_2021_1926537</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33999750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163</originalsourceid><addsrcrecordid>eNp9kN1KwzAYhoMobk4vQckNdOZnTZszZf7CYCcKOytpmrBI25Qkc_Q6vGFTu4lHHiXwPu_38T0AXGM0xyhHt4jkC5yzzZwggueYE5bS7ARMMUtxQgjbnILpwCQDNAEX3n8ghAjN0nMwoZRznqVoCr7WuyBto6BoK-iFVqGPX1H33nhoNVRtFdPgjKihFK1UDnYiGNUGD4NTIqgK7k3Yws76YDvlYvipIH1IpG21dU3sOVEZG7Yx63poHTRtUK03cVNjq139M-MvcwnOtKi9ujq8M_D-9Pi2fElW6-fX5f0qkZSxkPBM6rIqM8koIWTBicgVLaVaoDLLieSEMp7TkjBBtSSaLrTMabywzChTEjM6A-k4VzrrvVO66JxphOsLjIpBcnGUXAySi4Pk2LsZe92ubFT12zpajcDdCJhRwd66uiqC6GvrtIsWjS_o_zu-Ac1XkZE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Onal, Cem ; Yuce Sari, Sezin ; Yavas, Guler ; Oymak, Ezgi ; Birgi, Sumerya Duru ; Yigit, Ecem ; Guler, Ozan Cem ; Gultekin, Melis ; Akyurek, Serap ; Yildiz, Ferah</creator><creatorcontrib>Onal, Cem ; Yuce Sari, Sezin ; Yavas, Guler ; Oymak, Ezgi ; Birgi, Sumerya Duru ; Yigit, Ecem ; Guler, Ozan Cem ; Gultekin, Melis ; Akyurek, Serap ; Yildiz, Ferah</creatorcontrib><description>We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DCRT (265 patients, 41%) or with IMRT (381 patients, 59%) between April 2007 and August 2019 were retrospectively analyzed. The primary endpoints were treatment-related acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. The secondary endpoints were LC and overall survival (OS) and disease-free survival (DFS). Median follow-up time was 37 months. The rates for acute GI and GU toxicities of any grade for the entire group were 55.6% and 46.8%, respectively. Acute grade ≥2 GI toxicity was significantly less in patients treated with IMRT compared to those treated with 3DCRT (11.0% vs. 19.2%, p=.004). However, no significant difference grade ≥2 GU toxicities was observed between the 3DCRT and IMRT groups (15.1% vs. 11.0%; p=.15). Acute grade ≥2 GI and GU toxicities were higher in patients receiving systemic chemotherapy, while paraaortic field irradiation increases only the risk of acute grade ≥2 GI toxicity. Estimated 3-year late grade ≥3 GI toxicity rates in the 3DCRT- and IMRT-treated patients were 4.6% and 1.9% (p= .03), respectively. The patients treated with adjuvant ChT had higher rates of late serious GI complications than those without adjuvant ChT. No significant difference in terms of survival and disease control was observed between the 3DCRT and IMRT treatment groups. No significant factor for LC was found in the multivariate analysis. In this multicentric study involving one of largest patient population, we found that IMRT-treated EC patients showed comparable clinical outcomes but with a lower incidence of GI toxicities compared with those treated with 3DCRT.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.1080/0284186X.2021.1926537</identifier><identifier>PMID: 33999750</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Endometrial carcinoma ; Endometrial Neoplasms - radiotherapy ; Female ; Humans ; intensity modulated radiotherapy ; Radiation Injuries ; Radiotherapy Dosage ; Radiotherapy, Conformal - adverse effects ; Radiotherapy, Intensity-Modulated - adverse effects ; Retrospective Studies ; survival ; three-dimensional conformal radiotherapy ; toxicity</subject><ispartof>Acta oncologica, 2021-09, Vol.60 (9), p.1154-1160</ispartof><rights>2021 Acta Oncologica Foundation 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163</citedby><cites>FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33999750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onal, Cem</creatorcontrib><creatorcontrib>Yuce Sari, Sezin</creatorcontrib><creatorcontrib>Yavas, Guler</creatorcontrib><creatorcontrib>Oymak, Ezgi</creatorcontrib><creatorcontrib>Birgi, Sumerya Duru</creatorcontrib><creatorcontrib>Yigit, Ecem</creatorcontrib><creatorcontrib>Guler, Ozan Cem</creatorcontrib><creatorcontrib>Gultekin, Melis</creatorcontrib><creatorcontrib>Akyurek, Serap</creatorcontrib><creatorcontrib>Yildiz, Ferah</creatorcontrib><title>Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DCRT (265 patients, 41%) or with IMRT (381 patients, 59%) between April 2007 and August 2019 were retrospectively analyzed. The primary endpoints were treatment-related acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. The secondary endpoints were LC and overall survival (OS) and disease-free survival (DFS). Median follow-up time was 37 months. The rates for acute GI and GU toxicities of any grade for the entire group were 55.6% and 46.8%, respectively. Acute grade ≥2 GI toxicity was significantly less in patients treated with IMRT compared to those treated with 3DCRT (11.0% vs. 19.2%, p=.004). However, no significant difference grade ≥2 GU toxicities was observed between the 3DCRT and IMRT groups (15.1% vs. 11.0%; p=.15). Acute grade ≥2 GI and GU toxicities were higher in patients receiving systemic chemotherapy, while paraaortic field irradiation increases only the risk of acute grade ≥2 GI toxicity. Estimated 3-year late grade ≥3 GI toxicity rates in the 3DCRT- and IMRT-treated patients were 4.6% and 1.9% (p= .03), respectively. The patients treated with adjuvant ChT had higher rates of late serious GI complications than those without adjuvant ChT. No significant difference in terms of survival and disease control was observed between the 3DCRT and IMRT treatment groups. No significant factor for LC was found in the multivariate analysis. In this multicentric study involving one of largest patient population, we found that IMRT-treated EC patients showed comparable clinical outcomes but with a lower incidence of GI toxicities compared with those treated with 3DCRT.</description><subject>Endometrial carcinoma</subject><subject>Endometrial Neoplasms - radiotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>intensity modulated radiotherapy</subject><subject>Radiation Injuries</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Conformal - adverse effects</subject><subject>Radiotherapy, Intensity-Modulated - adverse effects</subject><subject>Retrospective Studies</subject><subject>survival</subject><subject>three-dimensional conformal radiotherapy</subject><subject>toxicity</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kN1KwzAYhoMobk4vQckNdOZnTZszZf7CYCcKOytpmrBI25Qkc_Q6vGFTu4lHHiXwPu_38T0AXGM0xyhHt4jkC5yzzZwggueYE5bS7ARMMUtxQgjbnILpwCQDNAEX3n8ghAjN0nMwoZRznqVoCr7WuyBto6BoK-iFVqGPX1H33nhoNVRtFdPgjKihFK1UDnYiGNUGD4NTIqgK7k3Yws76YDvlYvipIH1IpG21dU3sOVEZG7Yx63poHTRtUK03cVNjq139M-MvcwnOtKi9ujq8M_D-9Pi2fElW6-fX5f0qkZSxkPBM6rIqM8koIWTBicgVLaVaoDLLieSEMp7TkjBBtSSaLrTMabywzChTEjM6A-k4VzrrvVO66JxphOsLjIpBcnGUXAySi4Pk2LsZe92ubFT12zpajcDdCJhRwd66uiqC6GvrtIsWjS_o_zu-Ac1XkZE</recordid><startdate>20210902</startdate><enddate>20210902</enddate><creator>Onal, Cem</creator><creator>Yuce Sari, Sezin</creator><creator>Yavas, Guler</creator><creator>Oymak, Ezgi</creator><creator>Birgi, Sumerya Duru</creator><creator>Yigit, Ecem</creator><creator>Guler, Ozan Cem</creator><creator>Gultekin, Melis</creator><creator>Akyurek, Serap</creator><creator>Yildiz, Ferah</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20210902</creationdate><title>Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy</title><author>Onal, Cem ; Yuce Sari, Sezin ; Yavas, Guler ; Oymak, Ezgi ; Birgi, Sumerya Duru ; Yigit, Ecem ; Guler, Ozan Cem ; Gultekin, Melis ; Akyurek, Serap ; Yildiz, Ferah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Endometrial carcinoma</topic><topic>Endometrial Neoplasms - radiotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>intensity modulated radiotherapy</topic><topic>Radiation Injuries</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Conformal - adverse effects</topic><topic>Radiotherapy, Intensity-Modulated - adverse effects</topic><topic>Retrospective Studies</topic><topic>survival</topic><topic>three-dimensional conformal radiotherapy</topic><topic>toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onal, Cem</creatorcontrib><creatorcontrib>Yuce Sari, Sezin</creatorcontrib><creatorcontrib>Yavas, Guler</creatorcontrib><creatorcontrib>Oymak, Ezgi</creatorcontrib><creatorcontrib>Birgi, Sumerya Duru</creatorcontrib><creatorcontrib>Yigit, Ecem</creatorcontrib><creatorcontrib>Guler, Ozan Cem</creatorcontrib><creatorcontrib>Gultekin, Melis</creatorcontrib><creatorcontrib>Akyurek, Serap</creatorcontrib><creatorcontrib>Yildiz, Ferah</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onal, Cem</au><au>Yuce Sari, Sezin</au><au>Yavas, Guler</au><au>Oymak, Ezgi</au><au>Birgi, Sumerya Duru</au><au>Yigit, Ecem</au><au>Guler, Ozan Cem</au><au>Gultekin, Melis</au><au>Akyurek, Serap</au><au>Yildiz, Ferah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2021-09-02</date><risdate>2021</risdate><volume>60</volume><issue>9</issue><spage>1154</spage><epage>1160</epage><pages>1154-1160</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DCRT (265 patients, 41%) or with IMRT (381 patients, 59%) between April 2007 and August 2019 were retrospectively analyzed. The primary endpoints were treatment-related acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. The secondary endpoints were LC and overall survival (OS) and disease-free survival (DFS). Median follow-up time was 37 months. The rates for acute GI and GU toxicities of any grade for the entire group were 55.6% and 46.8%, respectively. Acute grade ≥2 GI toxicity was significantly less in patients treated with IMRT compared to those treated with 3DCRT (11.0% vs. 19.2%, p=.004). However, no significant difference grade ≥2 GU toxicities was observed between the 3DCRT and IMRT groups (15.1% vs. 11.0%; p=.15). Acute grade ≥2 GI and GU toxicities were higher in patients receiving systemic chemotherapy, while paraaortic field irradiation increases only the risk of acute grade ≥2 GI toxicity. Estimated 3-year late grade ≥3 GI toxicity rates in the 3DCRT- and IMRT-treated patients were 4.6% and 1.9% (p= .03), respectively. The patients treated with adjuvant ChT had higher rates of late serious GI complications than those without adjuvant ChT. No significant difference in terms of survival and disease control was observed between the 3DCRT and IMRT treatment groups. No significant factor for LC was found in the multivariate analysis. In this multicentric study involving one of largest patient population, we found that IMRT-treated EC patients showed comparable clinical outcomes but with a lower incidence of GI toxicities compared with those treated with 3DCRT.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>33999750</pmid><doi>10.1080/0284186X.2021.1926537</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0284-186X
ispartof Acta oncologica, 2021-09, Vol.60 (9), p.1154-1160
issn 0284-186X
1651-226X
language eng
recordid cdi_crossref_primary_10_1080_0284186X_2021_1926537
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Endometrial carcinoma
Endometrial Neoplasms - radiotherapy
Female
Humans
intensity modulated radiotherapy
Radiation Injuries
Radiotherapy Dosage
Radiotherapy, Conformal - adverse effects
Radiotherapy, Intensity-Modulated - adverse effects
Retrospective Studies
survival
three-dimensional conformal radiotherapy
toxicity
title Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A08%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20and%20safety%20analysis%20of%20endometrial%20cancer%20patients%20treated%20with%20postoperative%203D-conformal%20radiotherapy%20or%20intensity%20modulated%20radiotherapy&rft.jtitle=Acta%20oncologica&rft.au=Onal,%20Cem&rft.date=2021-09-02&rft.volume=60&rft.issue=9&rft.spage=1154&rft.epage=1160&rft.pages=1154-1160&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.1080/0284186X.2021.1926537&rft_dat=%3Cpubmed_cross%3E33999750%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-97cfbdb7c63222492a8e3bce40b782c9236983b26a3fc2f34fc83afeb736ec163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33999750&rfr_iscdi=true